Home  »  Business   »  Protagonist Therapeutics Inc. (NASDAQ: PTGX) Gains...

Protagonist Therapeutics Inc. (NASDAQ: PTGX) Gains 120.44% YTD: What’s Next?

Protagonist Therapeutics Inc. (NASDAQ:PTGX)’s traded shares stood at 1.68 million during the last session, with the company’s beta value hitting 1.84. At the close of trading, the stock’s price was $24.05, to imply a decrease of -4.87% or -$1.23 in intraday trading. The PTGX share’s 52-week high remains $27.41, putting it -13.97% down since that peak but still an impressive 71.27% since price per share fell to its 52-week low of $6.91. The company has a valuation of $1.15B, with an average of 4.4 million shares in intraday trading volume over the past 10 days and average of 1.63 million shares over the past 3 months.

Analysts have given a consensus recommendation of a Buy for Protagonist Therapeutics Inc. (PTGX), translating to a mean rating of 1.70. Of 6 analyst(s) looking at the stock, 0 analyst(s) give PTGX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.59.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Protagonist Therapeutics Inc. (NASDAQ:PTGX) trade information

After registering a -4.87% downside in the last session, Protagonist Therapeutics Inc. (PTGX) has traded red over the past five days. The stock hit a weekly high of 25.69 this Wednesday, 03/15/23, dropping -4.87% in its intraday price action. The 5-day price performance for the stock is -0.27%, and 49.94% over 30 days. With these gigs, the year-to-date price performance is 120.44%. Short interest in Protagonist Therapeutics Inc. (NASDAQ:PTGX) saw shorts transact 2.03 million shares and set a 2 days time to cover.

Analysts on Wall Street suggest a consensus price target of $34.17, implying an increase of 29.62% to the stock’s current value. The extremes give us $29.00 and $41.00 for target low and target high price respectively. As such, PTGX has been trading -70.48% off suggested target high and -20.58% from its likely low.

Protagonist Therapeutics Inc. (PTGX) estimates and forecasts

Looking at statistics comparing Protagonist Therapeutics Inc. share performance against respective industry, we note that the company has underperformed competitors. Protagonist Therapeutics Inc. (PTGX) shares are 183.61% up over the last 6 months, with its year-to-date growth rate lower than industry average at 5.54% against 9.90%. Revenue is forecast to grow 23.40% this quarter before falling -60.50% for the next one. The rating firms project that company’s revenue will grow 15.20% compared to the previous financial year.

Revenue forecast for the current quarter as set by 6 analysts is $5 million. Meanwhile, for the quarter ending Mar 2023, a total of 4 analyst(s) estimate revenue growth to $2.5 million.Earnings reports from the last fiscal year show that sales brought in $8.62 million and $25.72 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -42.00% before dropping -90.30% in the following quarter.

PTGX Dividends

Protagonist Therapeutics Inc. has its next earnings report out between May 02 and May 08. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Protagonist Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.

Protagonist Therapeutics Inc. (NASDAQ:PTGX)’s Major holders

Protagonist Therapeutics Inc. insiders hold 1.46% of total outstanding shares, with institutional holders owning 100.44% of the shares at 101.93% float percentage. In total, 100.44% institutions holds shares in the company, led by State Street Corporation. As of Sep 29, 2022, the company held over 4.68 million shares (or 9.51% of shares), all amounting to roughly $39.42 million.

The next major institution holding the largest number of shares is RTW Investments LP with 4.18 million shares, or about 8.49% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $35.21 million.

We also have SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Protagonist Therapeutics Inc. (PTGX) shares. Going by data provided on Dec 30, 2022, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF holds roughly 2.83 million shares. This is just over 5.75% of the total shares, with a market valuation of $30.85 million. Data from the same date shows that the other fund manager holds a little less at 1.39 million, or 2.83% of the shares, all valued at about 11.75 million.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts